BioRestorative Therapies, Inc. Common Stock (NV) financials
$2.33+0.87%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 | Q2 '23 Jun 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $23.2K | $19.6K | $11.8K | $303.3K | $25.0K | $43.3K | $233.6K | $89.1K | $35.0K | $19.3K | $30.7K | $64.5K |
| Gross profit | $15.8K | $18.0K | $1.2K | $294.6K | $22.1K | $40.0K | $215.4K | $82.6K | $35.0K | $19.3K | $30.7K | $64.5K |
| Gross margin | 68.1% | 91.7% | 10.4% | 97.1% | 88.4% | 92.3% | 92.2% | 92.7% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$3.4M | -$3.8M | -$3.7M | -$3.3M | -$4.8M | -$2.7M | -$2.3M | -$2.5M | -$4.1M | -$3.2M | -$3.1M | -$3.1M |
| Net income | -$2.2M | -$3.2M | -$3.0M | -$2.7M | -$5.3M | -$1.6M | -$1.1M | -$4.0M | -$2.2M | -$2.3M | $4.8M | -$5.7M |
| Net margin | −9298.3% | −16365.5% | −25748.1% | −875.8% | −21359.2% | −3778.6% | −467.2% | −4521.4% | −6352.2% | −11937.8% | 15531.8% | −8851.8% |
| Diluted EPS | $-2.40 | $-6.57 | $-6.60 | $-6.00 | $-12.80 | $-4.02 | $-2.60 | $-10.00 | $-6.60 | — | $7.80 | $-29.40 |
| EBITDA | -$3.3M | -$3.8M | -$3.7M | -$3.3M | -$4.8M | -$2.6M | -$2.2M | -$2.4M | -$4.1M | -$3.2M | -$3.1M | -$3.1M |
| Operating cash flow | -$3.8M | -$2.4M | -$2.9M | -$2.7M | -$2.8M | -$2.3M | -$1.7M | -$1.9M | -$2.3M | -$1.6M | -$1.2M | -$1.3M |
| Free cash flow | -$3.8M | -$2.5M | -$2.9M | -$2.7M | -$2.8M | -$2.4M | -$1.8M | -$1.9M | -$2.3M | -$1.7M | -$1.2M | -$1.3M |
| Diluted shares | 0.9M | 0.5M | 0.5M | 0.4M | 0.4M | 0.4M | 0.4M | 0.4M | 0.3M | — | 0.6M | 0.2M |
Balance sheet
| Period end | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.1M | $1.5M | $602.4K | $1.6M | $1.2M | $547.9K |
| Short-term investments | $479.4K | $1.4M | $3.9M | $5.8M | $7.9M | $10.2M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $4.6M | $4.1M | $5.6M | $8.5M | $10.3M | $12.3M |
| Total liabilities | $1.6M | $3.7M | $3.4M | $3.7M | $4.2M | $3.7M |
| Shareholders' equity | $3.0M | $356.7K | $2.2M | $4.8M | $6.1M | $8.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology